Display options
Cite
Hein S, Herrlein ML, Mhedhbi I, et al. Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses. Allergy. 2021;doi: 10.1111/all.15189.
Hein, S., Herrlein, M. L., Mhedhbi, I., Bender, D., Haberger, V., Benz, N., Eisert, J., Stingl, J., Dreher, M., Oberle, D., Schulze, J., Mache, C., Budt, M., Hildt, C., Wolff, T., & Hildt, E. (2021). Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses. Allergy, . https://doi.org/10.1111/all.15189
Hein, Sascha, et al. "Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses." Allergy vol. (2021). doi: https://doi.org/10.1111/all.15189
Hein S, Herrlein ML, Mhedhbi I, Bender D, Haberger V, Benz N, Eisert J, Stingl J, Dreher M, Oberle D, Schulze J, Mache C, Budt M, Hildt C, Wolff T, Hildt E. Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses. Allergy. 2021 Nov 25; doi: 10.1111/all.15189. Epub 2021 Nov 25. PMID: 34820854.
Copy Download .nbib Format: NLM
Share it on

Allergy. 2021 Nov 25; doi: 10.1111/all.15189. Epub 2021 Nov 25.

Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.

Allergy

Sascha Hein, Marie-Luise Herrlein, Ines Mhedhbi, Daniela Bender, Vanessa Haberger, Nuka Benz, Jonathan Eisert, Julia Stingl, Michael Dreher, Doris Oberle, Jessica Schulze, Christin Mache, Matthias Budt, Christoph Hildt, Thorsten Wolff, Eberhard Hildt

Affiliations

  1. Department of Virology, Paul-Ehrlich-Institute, Langen, Germany.
  2. Institute of Clinical Pharmacology, University Hospital of RWTH, Aachen, Germany.
  3. Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany.
  4. Division of Pharmacovigilance, Paul-Ehrlich-Institute, Langen, Germany.
  5. Robert-Koch-Institut, Influenza and Other Respiratory Viruses, Berlin, Germany.
  6. Main-Kinzig-Kliniken, Herzbachweg, Berlin, Germany.

PMID: 34820854 DOI: 10.1111/all.15189

Abstract

BACKGROUND: The mRNA vaccine BNT162b2 (Comirnaty, BioNTech/Pfizer) and the vaccine candidate CVnCoV (Curevac) each encode a stabilized spike protein of SARS-CoV2 as antigen but differ with respect to the nature of the mRNA (modified versus unmodified nucleotides) and the mRNA amount (30 μg versus 12 μg RNA). This study characterizes antisera elicited by these two vaccines in comparison to convalescent sera.

METHODS: Sera from BNT162b2 vaccinated healthcare workers, and sera from participants of a phase I trial vaccinated with 2, 4, 6, 8, or 12 μg CVnCoV and convalescent sera from hospitalized patients were analyzed by ELISA, neutralization tests, surface plasmon resonance (SPR), and peptide arrays.

RESULTS: BNT162b2-elicited sera and convalescent sera have a higher titer of spike-RBD-specific antibodies and neutralizing antibodies as compared to the CVnCoV-elicited sera. For all analyzed sera a reduction in binding and neutralizing antibodies was found for the lineage B.1.351 variant of concern. SPR analyses revealed that the CVnCoV-elicited sera have a lower fraction of slow-dissociating antibodies. Accordingly, the CVnCoV sera almost fail to compete with the spike-ACE2 interaction. The significance of common VOC mutations K417N, E484K, or N501Y focused on linear epitopes was analyzed using a peptide array approach. The peptide arrays showed a strong difference between convalescent sera and vaccine-elicited sera. Specifically, the linear epitope at position N501 was affected by the mutation and elucidates the escape of viral variants to antibodies against this linear epitope.

CONCLUSION: These data reveal differences in titer, neutralizing capacity, and affinity of the antibodies between BNT162b2- and CVnCoV-elicited sera, which could contribute to the apparent differences in vaccine efficacy.

© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Keywords: SARS-CoV-2; antisera; mRNA; vaccine; variants of concern

References

  1. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Front Immunol. 2020;11: 576622. - PubMed
  2. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018;14:e1007236. - PubMed
  3. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215-220. - PubMed
  4. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;180:1-12. - PubMed
  5. Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81:495-501. - PubMed
  6. Carneiro DC, Sousa JD, Monteiro-Cunha JP. The COVID-19 vaccine development: A pandemic paradigm. Virus Res. 2021;301: 198454. - PubMed
  7. Vasireddy D, Atluri P, Malayala SV, Vanaparthy R, Mohan G. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use. J Clin Med Res. 2021;13:204-213. - PubMed
  8. Yan Y, Pang Y, Lyu Z, et al. The COVID-19 Vaccines: Recent Development, Challenges and Prospects. Vaccines. 2021;9:1-16. - PubMed
  9. Wagner R, Meißner J, Grabski E, Sun Y, Vieths S, Hildt E. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. Allergy. 2021;1-11. - PubMed
  10. Rauch S, Roth N, Schwendt K, Fotin-Mleczek M, Mueller SO, Petsch B. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. 2021;6:57. - PubMed
  11. Verbeke R, Lentacker I, de Smedt SC, Dewitte H. The dawn of mRNA vaccines: The COVID-19 case. J Controlled Release. 2021;333:511-520. - PubMed
  12. Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021;601: 120586. - PubMed
  13. CureVac. CureVac Provides Update on Phase 2b_3 Trial of First-Generation COVID-19. CVnCoV. Curevac. 2021. - PubMed
  14. Cromer D, Reynaldi A, Steain M, Triccas JA, Davenport MP, Khoury DS. Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC).; 2021.trial: medRxiv: the preprint server for health sciences - PubMed
  15. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discovery. 2021;20(11):817-838. - PubMed
  16. Kremsner PG, Guerrero RAA, Arana E, et al. Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America. SSRN Electronic Journal. 2021;1-29. - PubMed
  17. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv: the preprint server for health sciences 2020. - PubMed
  18. Case JB, Bailey AL, Kim AS, Chen RE, Diamond MS. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology. 2020;548:39-48. - PubMed
  19. Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc. 1963;85:2149-2154. - PubMed
  20. Kühne Y, Reese G, Ballmer-Weber BK, et al. A Novel Multipeptide Microarray for the Specific and Sensitive Mapping of Linear IgE-Binding Epitopes of Food Allergens. Int Arch Allergy Immunol. 2015;166:213-224. - PubMed
  21. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115-119. - PubMed
  22. Kremsner PG, Mann P, Kroidl A, et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial. Wien Klin Wochenschr. 2021;1-11. - PubMed
  23. Wang Q, Zhang Y, Wu L, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181:894-904.e9. - PubMed
  24. Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, et al. Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates: bioRxiv: the preprint server for sciences, 2021. - PubMed
  25. Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. The New England Journal of Medicine. 2021;385:585-594. - PubMed
  26. Hoffmann M, Hofmann-Winkler H, Krüger N, et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021;36:1-9. - PubMed
  27. Obst R, van Santen H-M, Mathis D, Benoist C. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J Exp Med. 2005;201:1555-1565. - PubMed
  28. Roth N, Schön J, Hoffmann D, Thran M, Thess A, Mueller SO, et al. CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats, 2021. - PubMed
  29. Hoffmann D, Corleis B, Rauch S, Roth N, Mühe J, Halwe NJ, et al. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. Nat Commun. 2021;12(1). - PubMed

Publication Types

Grant support